ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "pain"

  • Abstract Number: 1799 • ACR Convergence 2023

    Association of Pregabalin vs Gabapentin with Incident Congestive Heart Failure in Patients with Non-Cancer Pain

    Elizabeth Park1, Laura Daniel2, Alyson Dickson3, Meghan Corriere4, Puran Nepal5, Kathi Hall4, Dale Plummer4, William Dupont4, Katherine Murray4, C. Michael Stein3, Wayne Ray4 and Cecilia Chung6, 1Columbia University Irving Medical Center, New York, NY, 2University of Miami, Nashville, TN, 3Vanderbilt University Medical Center, Nashville, TN, 4Vanderbilt University, Nashville, TN, 5University of Miami Health System and Miller School of Medicine, Miami, FL, 6University of Miami, Miami, FL

    Background/Purpose: Chronic pain affects 30% of all patients in developed countries, accounting for up to 35% of prescriptions in acute care settings. Non-opioid pain medications…
  • Abstract Number: 1981 • ACR Convergence 2023

    The Association Between X-ray Progression and Clinical Outcomes in Patients with Hand Osteoarthritis with 5-year Follow-up

    Olga Sleglova1, Jiri Baloun2, Jindriska Gatterova1, Xiao Svec1, Olga Ruzickova1, Karel Pavelka3 and Ladislav Senolt4, 1Rheumatology Institute, Prague, Czech Republic, 2Institute of Rheumatology, Prague, Czech Republic, 3Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, 4Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic

    Background/Purpose: Hand osteoarthritis (HOA) is a heterogeneous disorder with two main subtypes, non-erosive and erosive. The progression of HOA is assessed by various radiographic scoring…
  • Abstract Number: 2524 • ACR Convergence 2023

    Relation of Pain Sensitivity to Forces While Walking in Adults with and Without Knee Pain: The Multicenter Osteoarthritis (MOST) Study

    Patrick Corrigan1, Cara Lewis2, Kerry Costello3, Deepak Kumar2, David Felson2, Tuhina Neogi4, Laura Frey Law5, Michael LaValley6, Michael Nevitt7, Beth Lewis8 and Joshua Stefanik9, 1Saint Louis University, St. Louis, MO, 2Boston University, Boston, MA, 3University of Florida, Gainesville, FL, 4Boston University School of Medicine, Boston, MA, 5University of Iowa, Iowa City, IA, 6Boston University School of Public Health, Arlington, MA, 7University of California San Francisco, San Francisco, CA, 8University of Alabama at Birimingham, Birmingham, AL, 9Northeastern University, Boston, MA

    Background/Purpose: Knee osteoarthritis (KOA) is a leading cause of pain and disability worldwide with no definitive treatment. There is a need to identify mechanisms that…
  • Abstract Number: 0413 • ACR Convergence 2023

    Transcriptomic Analysis of Peripheral Blood Mononuclear Cells Reveals Pain and Inflammation Specific Alterations in Difficult-to-treat Rheumatoid Arthritis

    Lilla Gunkl-Tóth1, Gábor Sütő2, Gábor Kumánovics3, József Kun4, Péter Urbán5, Attila Gyenesei5, Panna Királyhidi6, Georg Schett7, György Nagy8 and Zsuzsanna Helyes9, 1Department of Pharmacology and Pharmacotherapy, University of Pécs, Hungary; Eötvös Loránd Research Network, University of Pécs, Chronic Pain Research Group, Budapest, Hungary, 2Second Department of Medicine and Nephrology-Diabetes Centre, University of Pécs, Pécs, Hungary, 3Department of Rheumatology and Immunology, Medical School, University of Pécs, Pécs, Hungary, 4Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary; Bioinformatics Research Group, Genomics and Bioinformatics Core Facility, Szentágothai Research Centre, University of Pécs, Budapest, Hungary, 5Bioinformatics Research Group, Genomics and Bioinformatics Core Facility, Szentágothai Research Centre, University of Pécs, Pécs, Hungary, Pécs, Hungary, 6Department of Genetics, Cell- and Immunobiology, Semmelweis University School of Medicine, Budapest, Hungary, 7Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 8Department of Rheumatology and Clinical Immunology, Semmelweis University School of Medicine; Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary; Heart and Vascular Centre, Semmelweis University, Budapest, Hungary, 9Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary; Eötvös Loránd Research Network, University of Pécs, Chronic Pain Research Group, Pécs, Hungary; National Laboratory for Drug Research and Development, Pécs, Hungary

    Background/Purpose: Despite novel treatment strategies in rheumatoid arthritis (RA), approximately 20-30% of patients remain symptomatic. The EULAR definition of difficult-to-treat (D2T) RA has recently been…
  • Abstract Number: 0865 • ACR Convergence 2023

    Reactive Oxygen Species-scavenging Nanoparticles Target Macrophage Polarization for Osteoarthritis Therapy

    Caifeng Deng1, Yongbing Xiao2, Xuan Zhao1, Hui Li2, Yuxiao Chen1, Chao Zeng2 and Guanghua Lei2, 1Xiangya Hospital, Changsha, China, 2Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China

    Background/Purpose: Unbalanced M1/M2 polarization of synovial macrophages plays vital roles in the symptomatic and structural progression of osteoarthritis (OA). The accumulation of intracellular reactive oxygen…
  • Abstract Number: 1290 • ACR Convergence 2023

    Development of a Genetic Risk Score for Pain in Rheumatoid Arthritis

    Katie McMenamin1, Kristin Wipfler2, Austin Wheeler3, Grant Cannon4, K Wysham5, Brian Sauer6, Bryant England3, Kaleb Michaud3, Ted R Mikuls7 and Joshua Baker8, 1Boston University, Boston, MA, 2FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 3University of Nebraska Medical Center, Omaha, NE, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5VA Puget Sound/University of Washington, Seattle, WA, 6Salt Lake City VA/University of Utah, Salt Lake City, UT, 7Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 8University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Pain in rheumatoid arthritis (RA) is multifactorial and involves processes beyond inflammation such as peripheral and central pain processing. Several genes have been associated…
  • Abstract Number: 1812 • ACR Convergence 2023

    Duloxetine and the Risk for Cardiovascular Events in US Veterans with Non-Cancer Pain

    Laura Daniel1, Alyson Dickson2, Puran Nepal1, Otis Wilson3, Adriana Hung2, Dale Plummer3, William Dupont3, Katherine Murray3, C. Michael Stein2, Wayne Ray3 and Cecilia Chung4, 1University of Miami, Nashville, TN, 2Vanderbilt University Medical Center, Nashville, TN, 3Vanderbilt University, Nashville, TN, 4University of Miami, Miami, FL

    Background/Purpose: Duloxetine is a serotonin-norepinephrine reuptake inhibitor approved by the FDA for the treatment of different forms of chronic pain. Because of its adrenergic activity,…
  • Abstract Number: 1982 • ACR Convergence 2023

    Effect of Denosumab on Knee Pain and Bone Marrow Lesions in Symptomatic Knee Osteoarthritis

    Terence O'Neill1, Matthew Parkes1, Michael Bowes2, Richard Hodgson1 and David Felson3, 1University of Manchester, Manchester, United Kingdom, 2Imorphics, Manchester, United Kingdom, 3Boston University, Boston, MA

    Background/Purpose: There are currently no licensed therapies which reduce progression of knee OA. Current therapies focus on reducing pain, have limited effect, and some have…
  • Abstract Number: 2525 • ACR Convergence 2023

    Comparing Patellar Tendon Characteristics Between Adults with and Without Knee Pain

    Samantha Price1, Karin Silbernagel2, David Felson3, Joshua Stefanik4 and Patrick Corrigan1, 1Saint Louis University, St. Louis, MO, 2University of Delaware, Avondale, PA, 3Boston University, Boston, MA, 4Northeastern University, Boston, MA

    Background/Purpose: Knee pain is one of the most common types of joint pain leading to disability, limited physical activity, and reduced quality of life. While…
  • Abstract Number: 0429 • ACR Convergence 2023

    Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Rheumatoid Arthritis: Results from a Randomized Phase 3 Study

    Peter C. Taylor1, David Walsh2, Tsutomu Takeuchi3, Bruno Fautrel4, Janet Pope5, Andrew Garrison6, Yanna Song6, Sara K. Penn6, Ralph Lippe7, Diane Caballero8 and Arthur Kavanaugh9, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2University of Nottingham, Nottingham, United Kingdom, 3Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, 4Sorbonne Université APHP, Paris, France, 5University of Western Ontario, London, ON, Canada, 6AbbVie, Inc., North Chicago, IL, 7AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 8AbbVie, Inc., Chicago, IL, 9University of California San Diego, School of Medicine, Riverside, CA

    Background/Purpose: Rapid and sustained pain control is an important goal for patients (pts) with rheumatoid arthritis (RA). Control of inflammation in RA does not always…
  • Abstract Number: 0867 • ACR Convergence 2023

    Pentosan Polysulfate Sodium, a Glycosaminoglycan Mimetic Demonstrates Durable Effects on Pain, Function and Joint Structure in Canine Naturally Occurring Osteoarthritis

    Ravi Krishnan1, Catherine Stapledon2, Christian Reiter2, Stewart Ryan3, Sebastien Bauquier3 and Thierry Beths3, 1Paradigm Biopharmaceuticals, Adelaide, Australia, 2Paradigm Biopharmaceuticals, Melbourne, Australia, 3U-Vet Werribee Animal Hospital, University of Melbourne, Melbourne, Australia

    Background/Purpose: Pentosan Polysulfate sodium (PPS) is a semi-synthetic polysaccharide and a glycosaminoglycan mimetic. The multiple actions of PPS involve anti-inflammatory effects via inhibition of NF-κB;…
  • Abstract Number: 1330 • ACR Convergence 2023

    Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial

    John Lampa1, Dan Nordstrom2, Ronald van Vollenhoven3, Merete Hetland4, Espen A Haavardsholm5, Mikkel Østergaard6, Anna Rudin7, Marte Schrumpf Heiberg5, Michael Nurmohamed3, Bjorn Gudbjornsson8, Kristina Lend9, Kim Hørslev-Petersen10, Tuulikki Sokka-Isler11, Gerdur Maria Grondal12, Simon Krabbe13, Joakim Lindqvist14, Anna-Karin Hultgård Ekwall15, Daniel Glinatsi16, Meliha Kapetanovic17, Cidem Gentline14, Anna-Birgitte Aga18, Heikki Relas2, Tove Lorenzen19, Giovanni Cagnotto20, Johan Back21, Oliver Hendricks22, Bas Dijkshoorn23, Kajsa Öberg24, Maud-Kristine Aga Ljoså25, Eli Brodin26, Hanne Merete Lindegaard27, Annika Söderbergh28, Milad Rizk29, Alf Kastbom30, Per Larsson31, Line Uhrenholt32, Søren Just33, David J Stevens34, Trine B Laurberg35, Gunnstein Bakland36, Inge Olsen37, Joseph Sexton18 and Till Uhlig18, 1Stockholm County, Hãsselby, Sweden, 2Helsinki University Hospital, Helsinki, Finland, 3Amsterdam University Medical Centers, Amsterdam, Netherlands, 4Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, 5Diakonhjemmet Hospital, Oslo, Norway, 6Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, 7Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 8Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, 9Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, 10University of Southern Denmark, Odense, Denmark, 11Jyvaskyla Central Hospital, Jyväskylä, Finland, 12Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, 13Herlev-Gentofte University Hospital, Herlev, Denmark, 14Karolinska University Hospital, Stockholm, Sweden, 15Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Kullavik, Sweden, 16Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Sweden, 17Lund University and Skåne University Hospital, Lund, Sweden, 18Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 19Silkeborg University Hospital, Silkeborg, Denmark, 20Skåne University Hospital, Lund, Sweden, 21Uppsala University Hospital, Uppsala, Sweden, 22Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, 23Amsterdam Rheumatology and Immunology Center, Location Reade, Amsterdam, Netherlands, 24Falu Hospital, Falun, Sweden, 25Ålesund Hospital, Ålesund, Norway, 26Haukeland University Hospital, Bergen, Norway, 27Odense Hospital, Odense, Denmark, 28Örebro University Hospital, Örebro, Sweden, 29Västmanlands Hospital Västerås, Västerås, Sweden, 30Linköping University, Linköping, Sweden, 31Academic Specialist Center, Stockholm, Sweden, 32Aalborg University Hospital, Aalborg, Denmark, 33Section of Rheumatology, Department of Medicine, Odense University Hospital – Svendborg Hospital, Odense, Denmark, 34St. Olavs Hospital, Trondheim, Norway, 35Aarhus University Hospital, Aarhus, Denmark, 36University Hospital of North Norway, Tromsø, Norway, 37Oslo University Hospital, Oslo, Norway

    Background/Purpose: The optimal first-line treatment of patients with early rheumatoid arthritis (eRA) is not established. Methods: In this investigator-initiated, randomized, open-label study (NCT01491815), patients with…
  • Abstract Number: 1819 • ACR Convergence 2023

    Clinical Indications Associated with New Opioid Use for Pain Management in the United Kingdom Using National Primary Care Data

    Max Lyon, Carlos Ramirez Medina, Elinor Davies and Meghna Jani, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom

    Background/Purpose: Prescription opioids for non-cancer pain in the UK have increased considerably over the past two decades, alongside a rise in associated harms. Despite the…
  • Abstract Number: 1990 • ACR Convergence 2023

    Effects of Exercise on Movement-Evoked Pain in People with Knee Osteoarthritis

    Ehyun Kim1, Tuhina Neogi2, Benjamin Senderling1, Mary Gheller1, Lee Marinko1, Michael LaValley3, Lukas Adamowicz4, Pirinka Georgiev4, Charmaine Demanuele4, Paul Wacnik4 and Deepak Kumar1, 1Boston University, Boston, MA, 2Boston University School of Medicine, Boston, MA, 3Boston University School of Public Health, Arlington, MA, 4Pfizer Inc., Cambridge, MA

    Background/Purpose: Movement-evoked pain (MEP), i.e., pain that appears with or is made worse by movement, is a common complaint in people with knee osteoarthritis (OA).…
  • Abstract Number: 2565 • ACR Convergence 2023

    The Problem of Pain in Rheumatology: A Population-based Study of Annual Trends in Pain Management Modalities in Patients with Autoimmune Rheumatic Diseases in the United States, 2007-2021

    Titilola Falasinnu1, Di Lu2 and Matthew Baker3, 1Stanford School of Medicine, Palo Alto, CA, 2Stanford School of Medicine, Stanford, CA, 3Stanford University, Menlo Park, CA

    Background/Purpose: Autoimmune rheumatic diseases (ARD) such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are salient causes of disability, functional limitations, reduced quality of…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 37
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology